This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
marijuana: Archive
Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?
by Sundeep Ganoria
Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.
JAZZNegative Net Change TLRYNegative Net Change GTBIFNegative Net Change
biotechs marijuana medical
ACB Stock Down 28% in Three Months: Time to Buy the Dip or Cash Out?
by Sundeep Ganoria
Aurora Cannabis' shares plunge 28% in three months as a cautious fiscal 2027 outlook overshadows record medical cannabis growth and global expansion.
ACBNegative Net Change CGCNegative Net Change TLRYNegative Net Change
marijuana medical
VFF Stock Loses 27% in Three Months: Time to Invest or Exit?
by Sundeep Ganoria
Village Farms has slid 27% in three months despite strong international cannabis growth. Can European expansion outweigh rising competition and pricing risks?
VFFNegative Net Change TLRYNegative Net Change ACBNegative Net Change
marijuana medical pot-stocks
TLRY Plans Strategic Medical Cannabis Expansion: Time to Buy or Sell?
by Sundeep Ganoria
Tilray expands its medical cannabis strategy with HelloMD, adding virtual patient access as investors weigh growth potential against ongoing profitability challenges.
TLRYNegative Net Change CRONPositive Net Change ACBNegative Net Change
marijuana medical pot-stocks
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying?
by Sundeep Ganoria
Cronos Group posts 40% Q1 revenue growth, gains share in Canada and expands abroad, but fierce cannabis competition keeps investors cautious.
CRONPositive Net Change TLRYNegative Net Change ACBNegative Net Change
marijuana medical pot-stocks
GTBIF Stock Climbs 17.5% in Three Months: Time to Invest or Cash Out?
by Sundeep Ganoria
Green Thumb has surged 17.5% in three months as regulatory progress, Q1 growth and buybacks lift sentiment, but competition and pricing pressure persist.
GTBIFNegative Net Change CRLBFNegative Net Change TRLVNegative Net Change
marijuana medical pot-stocks
Cannabis Operator Cresco Down 28.5% YTD: How to Play the Stock?
by Sundeep Ganoria
CRLBF is down 28.5% YTD as revenue pressure and competition persist, but retail expansion and improving estimates could shape its next move.
GTBIFNegative Net Change CRLBFNegative Net Change VRNOPositive Net Change
marijuana medical pot-stocks
Sin Stocks Under the Microscope: Risks, Returns & Reality
by Rajani Lohia
Sin stocks, including alcohol, tobacco, cannabis, firearms and gambling, draw investors' attention with steady demand and dividends, but ESG pressure, taxes and regulation are reshaping the risk/reward.
MOPositive Net Change MCRIPositive Net Change SAMPositive Net Change CHDNPositive Net Change TPBPositive Net Change
consumer-staples marijuana thematic tobacco
Verano Advances U.S. Exchange Uplisting Plans: Time to Invest?
by Sundeep Ganoria
VRNO's reverse split and prior U.S. redomestication support potential exchange uplisting plans as the company expands stores and product offerings.
GTBIFNegative Net Change CURLFPositive Net Change VRNOPositive Net Change
marijuana medical pot-stocks
Curaleaf Prepares for US Exchange Uplisting: Time to Invest?
by Sundeep Ganoria
CURLF's reverse stock split and Delaware domestication plan signal preparation for a potential U.S. uplisting as revenue and international growth improve.
TLRYNegative Net Change GTBIFNegative Net Change CURLFPositive Net Change
marijuana medical pot-stocks